E Fund Management’s Solid Biosciences SLDB Stock Holding History

E Fund Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$101K	Buy	+10,121	New	+$76.7K	﹤0.01%	473

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

E Fund Management's SLDB Position: Q2 2026 in Review

E Fund Management opened a new position in Solid Biosciences (SLDB) in Q2 2026: 10,121 shares worth $101K. The stake represents ﹤0.01% of the portfolio and ranks #473 among its holdings.

157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

E Fund Management held 10,121 shares of Solid Biosciences worth $101K as of Q2 2026.
Solid Biosciences was a new E Fund Management position in Q2 2026.
Solid Biosciences made up ﹤0.01% of E Fund Management's portfolio in Q2 2026, its #473 holding.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.